Healthcare
Legend Biotech Corporation(LEGN)
Live Price
Offline$27.93
-16.68% today
1Y Change
-16.45%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $4.35B
- Revenue Growth
- +64.5%
- EPS Growth
- -64.9%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Legend Biotech Corporation (LEGN) is a Healthcare stock with a market cap of $4.35B and listed on NASDAQ. The stock last traded around $27.93 and down 16.5% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +64.5%, EPS growth of -64.9%, a dividend yield of 0.0%. What stands out right now is revenue +64.5%, EPS -64.9%, free cash flow -6.3% with operating margin -13.2% and ROIC -9.5%. Valuation sits in the middle of the pack at price/sales 4.2. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines LEGN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+64.5% vs +7.6% peer median
Operating Margin
Below sector median
-13.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +64.5% and EPS is at -64.9%, with operating margin around -13.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +1.5% | -4.7% | +23.4% |
2026 Mar 10, 2026 | +52.9% | +3.6% | -5.2% | -6.4% |
2025 Nov 12, 2025 | +15.4% | -0.5% | -10.2% | -26.2% |
Benchmark Edge
LEGN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LEGN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LEGN Max Drawdown
-62.43%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LEGN and SPY.
Company Overview
Legend Biotech Corporation
NASDAQ Global Select
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
- Leadership
- Ying Huang
- IPO Date
- Jun 5, 2020
- Employees
- 2.6k
- Street Address
- 2101 Cottontail Lane
- Mailing
- Somerset, NJ, 08873
- Region
- Somerset, NJ, US
- Reporting Currency
- USD
- Investor Line
- 732 317 5050
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.2
- Price/Book
- 4.3
Growth
- Revenue
- +64.5%
- EPS
- -64.9%
- Free Cash Flow
- -6.3%
Profitability
- Gross Margin
- 60.3%
- Operating Margin
- -13.2%
- Net Margin
- -28.8%
- ROE
- -29.2%
- ROIC
- -9.5%
Balance Sheet
- Debt/Equity
- 0.41
- Current Ratio
- 1.96
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.